Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL A GOZZI

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1316931413
CMS profile
196129
Location
SUITLAND, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$132,811.19

300 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL A GOZZI

NPI 1316931413 · CMS profile ID 196129

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

SUITLAND, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316931413?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL A GOZZI, NPI 1316931413, CMS profile ID 196129. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316931413?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DANIEL A GOZZI, NPI 1316931413, CMS profile ID 196129. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316931413?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DANIEL A GOZZI, NPI 1316931413, CMS profile ID 196129, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1316931413?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

300 matching records · $132,811.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 300 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 300.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Xeris Pharmaceuticals, Inc. $16.3310/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056452397 CMS
SANOFI-AVENTIS U.S. LLC $941.7909/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049877893 CMS
SANOFI-AVENTIS U.S. LLC $226.9709/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049877897 CMS
SANOFI-AVENTIS U.S. LLC $350.0009/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049877901 CMS
SANOFI-AVENTIS U.S. LLC $49.9809/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049877905 CMS
SANOFI-AVENTIS U.S. LLC $49.9809/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049877909 CMS
SANOFI-AVENTIS U.S. LLC $124.9809/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049877911 CMS
Novartis Pharmaceuticals Corporation $23.0609/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992266213 CMS
Horizon Therapeutics plc $22.0409/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987009529 CMS
MannKind Corporation $19.3509/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056266023 CMS
MannKind Corporation $15.5809/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056266017 CMS
Insulet Corporation $17.9909/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016957015 CMS
Lilly USA, LLC $7.3109/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031329503 CMS
Lilly USA, LLC $23.3709/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031351409 CMS
Corcept Therapeutics $25.9909/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050809345 CMS
Lilly USA, LLC $900.0009/19/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031358871 CMS
Insulet Corporation $15.8109/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016957013 CMS
Xeris Pharmaceuticals, Inc. $19.9209/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056452413 CMS
Lilly USA, LLC $23.1309/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031351401 CMS
Novartis Pharmaceuticals Corporation $24.1908/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992266209 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $11.7708/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996938803 CMS
Abbott Laboratories $18.4508/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018905883 CMS
Novo Nordisk Inc $11.6708/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000414139 CMS
Dexcom, Inc. $46.8808/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054768411 CMS
Amneal Pharmaceuticals LLC $20.8508/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053496447 CMS
Lilly USA, LLC $22.1608/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031329501 CMS
Lilly USA, LLC $29.8608/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031448071 CMS
MannKind Corporation $19.1108/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056266011 CMS
Amneal Pharmaceuticals LLC $25.2008/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053496443 CMS
Lilly USA, LLC $31.4008/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031351459 CMS
Lilly USA, LLC $28.8808/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031351471 CMS
Astellas Pharma US Inc $23.5508/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034355693 CMS
PFIZER INC. $21.7207/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049314150 CMS
Lilly USA, LLC $21.3107/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031329491 CMS
Abbott Laboratories $20.0607/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018897599 CMS
Lilly USA, LLC $28.0707/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031324661 CMS
Tandem Diabetes Care, Inc. $21.3907/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060266469 CMS
Horizon Therapeutics plc $24.2407/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987009525 CMS
Novo Nordisk Inc $938.0007/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002650665 CMS
Ascensia Diabetes Care Us Inc. $16.3207/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017936567 CMS
Lilly USA, LLC $25.8407/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031351387 CMS
Novo Nordisk Inc $938.0007/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002650653 CMS
Amneal Pharmaceuticals LLC $13.3807/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053496437 CMS
Lilly USA, LLC $14.5507/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031448067 CMS
ABBVIE INC. $900.0007/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997375969 CMS
Lilly USA, LLC $23.9307/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031329519 CMS
Novo Nordisk Inc $938.0006/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002650645 CMS
ABBVIE INC. $900.0006/28/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997375967 CMS
Nevro Corp. $30.2806/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051676987 CMS
Lilly USA, LLC $4.4606/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031357109 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $144,097.98 350
PY2020 $98,147.03 201
PY2021 $146,449.65 379
PY2022 $188,626.29 400
PY2023 $132,811.19 300
PY2024 $245,129.87 358
PY2025 $231,687.84 378

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2020 Principal investigator $30,742.00 13
PY2019 Principal investigator $2,260.63 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

13 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $900.00 12/31/2020 Non-covered Recipient Entity
BLUE THEORY CLINICALS TRIALS LLC CLINICAL TRIAL
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721329619
Principal investigator 1 Allergan, Inc. $400.00 12/03/2020 Non-covered Recipient Entity
BLUE THEORY CLINICALS TRIALS LLC CLINICAL TRIAL
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721329541
Principal investigator 1 Allergan, Inc. $2,500.00 12/03/2020 Non-covered Recipient Entity
BLUE THEORY CLINICALS TRIALS LLC CLINICAL TRIAL
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721329543
Principal investigator 1 Allergan, Inc. $400.00 12/03/2020 Non-covered Recipient Entity
BLUE THEORY CLINICALS TRIALS LLC CLINICAL TRIAL
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721329545
Principal investigator 1 Allergan, Inc. $2,500.00 12/03/2020 Non-covered Recipient Entity
BLUE THEORY CLINICALS TRIALS LLC CLINICAL TRIAL
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721329547
Principal investigator 1 Allergan, Inc. $315.00 09/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721299347
Principal investigator 1 Allergan, Inc. $327.00 09/03/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721295071
Principal investigator 1 Allergan, Inc. $2,000.00 07/21/2020 Non-covered Recipient Entity
BLUE THEORY CLINICALS TRIALS LLC CLINICAL TRIAL
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721329343
Principal investigator 1 Allergan, Inc. $9,000.00 07/21/2020 Non-covered Recipient Entity
BLUE THEORY CLINICALS TRIALS LLC CLINICAL TRIAL
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721329345
Principal investigator 1 Allergan, Inc. $700.00 04/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721269541
Principal investigator 1 Allergan, Inc. $2,000.00 04/07/2020 Non-covered Recipient Entity
BLUE THEORY CLINICALS TRIALS LLC CLINICAL TRIAL
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721329179
Principal investigator 1 Allergan, Inc. $9,000.00 04/07/2020 Non-covered Recipient Entity
BLUE THEORY CLINICALS TRIALS LLC CLINICAL TRIAL
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721329181
Principal investigator 1 Allergan, Inc. $700.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721251735